title: Aldosterone antagonists destabilize the mineralocorticosteroid receptor.
abstract: To elucidate the mechanism of action of aldosterone antagonists, we studied the interaction of spironolactone with the chick mineralocorticosteroid receptor (MR). Intestinal cytosol contains specific spironolactone-binding sites (Kd approximately 3 nM; max. no. of binding sites approximately 100 fmol/mg of protein) that have been identified as MRs by competition experiments with steroid ligands and with the monoclonal anti-idiotypic antibody H10E that interacts with aldosterone-binding domain of the MR. Binding studies indicate that aldosterone and spironolactone bind to the MR through a common site that encompasses the epitope recognized by H10E. At 4 degrees C, spironolactone dissociates much more rapidly from the cytosol 8-9 S form of MR (t1/2 38 min) than does aldosterone (t1/2 3240 min). A high dissociation rate was also observed for progesterone, a natural aldosterone antagonist (t1/2 84 min). The covalent linkage of the 90 kDa heat shock protein (hsp90) to the ligand-binding subunit of MR with dimethyl pimelimidate did not notably modify the rate of dissociation of spironolactone from the receptor (t1/2 96 min), excluding the possibility that the rapid dissociation rate of the antagonist was related to hsp90 release. The effects of aldosterone and the two anti-mineralocorticosteroids on the 8-9 S heterooligomeric structure of the MR differed strikingly. Using low-salt density-gradient centrifugation analysis, aldosterone-labelled receptors were recovered as 8-9S complexes, whereas 4 S entities were detected after spironolactone and progesterone binding. This indicated that, under the experimental conditions used, aldosterone antagonists facilitate hsp90 release and thus do not stabilize the non-DNA-binding 8-9S form of MR. We propose that the combination of rapid dissociation of the ligand and a weakened hsp90-receptor interaction is involved in the anti-mineralococorticosteroid activity of aldosterone antagonists.
authors.affiliation: Lab. Hormones, INSERM U 33, Bicêtre, France.
authors.forename: B
authors.initials: B
authors.lastname: Couette
authors.forename: M
authors.initials: M
authors.lastname: Lombes
authors.forename: E E
authors.initials: EE
authors.lastname: Baulieu
authors.forename: M E
authors.initials: ME
authors.lastname: Rafestin-Oblin
mesh_terms: D000450:Aldosterone / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D001665:Binding Sites; D002645:Chickens; D006360:Heat-Shock Proteins / Q000378:metabolism; D066298:In Vitro Techniques; D007700:Kinetics; D000451:Mineralocorticoid Receptor Antagonists / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D011374:Progesterone / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D013148:Spironolactone / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D006360:Heat-Shock Proteins; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid; D013148:Spironolactone; D000450:Aldosterone; D011374:Progesterone